| Identification | Back Directory | [Name]
(2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL | [CAS]
212844-54-7 | [Synonyms]
NG 95
CS-2003
PURVALANOL B
NG 95; NG95; NG-95
Purvalanol B, >=96%
Purvalanol B(NG 95)
(R)-2-Chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzo
(R)-2-CHLORO-4-(2-(1-HYDROXY-3-METHYLBUTAN-2-YLAMINO)-9-ISOPROPYL-9H-PURIN-6-YLAMINO)BENZOIC ACID
(2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL
(2R)-2-((6-((3-Chloro-4-carboxyphenyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-3-methyl-1-butanol
NG 95, (2R)-2-[[6-[(3-Chloro-4-carboxyphenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanol
Benzoic acid, 2-chloro-4-[[2-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]- | [Molecular Formula]
C20H25ClN6O3 | [MDL Number]
MFCD04118312 | [MOL File]
212844-54-7.mol | [Molecular Weight]
432.9 |
| Chemical Properties | Back Directory | [Melting point ]
58.5 °C | [Boiling point ]
660.6±65.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,Store in freezer, under -20°C | [solubility ]
DMSO: 37 mg/mL, soluble
| [form ]
solid
| [pka]
2.81±0.25(Predicted) | [color ]
White to light yellow | [InChIKey]
ZKDXRFMOHZVXSG-HNNXBMFYSA-N |
| Hazard Information | Back Directory | [Description]
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Purvalanol B is a CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively). It is inactive against Cdk4/cyclin D1 as well as several other protein kinases. Purvalanol B is a 2,6,9-trisubstituted purine that, at micromolar doses, inhibits the growth of parasites, including Plasmodium. | [Uses]
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Purvalanol B is a CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively). It is inactive against Cdk4/cyclin D1 as well as several other protein kinases. Purvalanol B is a 2,6,9-trisubstituted purine that, at micromolar doses, inhibits the growth of parasites, including Plasmodium. | [Definition]
ChEBI: Purvalanol B is a purvalanol. It has a role as a protein kinase inhibitor. | [Biological Activity]
Cyclin-dependent kinase inhibitor. IC 50 values are 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. Selective over a range of other protein kinases (IC 50 > 10,000 nM). Shown to have antiproliferative properties, mediated by p42/p44 MAPK. | [storage]
Store at -20°C | [References]
[1] SERA T. [Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors].[J]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 2007, 52 13 Suppl: 1812-1813.
[2] M KNOCKAERT. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.[J]. Chemistry & biology, 2000, 7 6: 411-422. DOI: 10.1016/s1074-5521(00)00124-1
[3] KRISTEN M BULLARD Susan M K Carolyn Broccardo. Effects of cyclin-dependent kinase inhibitor Purvalanol B application on protein expression and developmental progression in intra-erythrocytic Plasmodium falciparum parasites.[J]. Malaria Journal, 2015: 147. DOI: 10.1186/s12936-015-0655-x |
|
|